- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Melinda Magyari Addresses the Use of Disease-Modifying MS Therapies in Children
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, addresses the current state of knowledge on using disease-modifying therapies to treat children with multiple sclerosis (MS).
Transcript
What is the current understanding about how to use disease-modifying therapies in children and adolescents with MS?
We don’t know a lot about it. This was my question looking at my own registry. I haven't really seen many similar studies published from other countries to see whether those not-existing guidelines has been interpreted the same way as we did in Denmark. So it would, I would encourage everybody having a cohort registry to publish these data.
